<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61518">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305056</url>
  </required_header>
  <id_info>
    <org_study_id>CARBONOMIC</org_study_id>
    <nct_id>NCT02305056</nct_id>
  </id_info>
  <brief_title>Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)</brief_title>
  <acronym>CARBONOMIC</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to follow tumoral proteins metabolism by in vivo no radioactive
      isotopic tagging (carbon 13 and nitrogen 15).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project aims to study protein turnover in glioblastoma using mass spectrometry after
      13C-valine incorporation. This will allow to identify proteins in circulation secreted by
      tumor which could be diagnostic and pronostic biomarkers in patients With High-grade Glioma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass spectrometry measurement of C13 labelled proteins</measure>
    <time_frame>during 30 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>High-grade Glioma</condition>
  <arm_group>
    <arm_group_label>C13 N15 Valine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention C13 N15 Valine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C13 N15 Valine</intervention_name>
    <description>C13 N15 Valine administration</description>
    <arm_group_label>C13 N15 Valine</arm_group_label>
    <other_name>CARBONOMIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more or equal than 18 years old

          -  patient affiliated to social security or similarly regime

          -  informed consent form signed

          -  High-grade Glioma tumor suspicion

          -  Resective surgery indication

          -  Hematological assessment :

               -  neutrophils &gt; 1500/mm3

               -  Platelet &gt; 150 000

               -  blood Creatinin normal

               -  alkaline Phosphatases and transaminases no more than two times normal

               -  Bilirubin &lt; 1.5 times normal

        Exclusion Criteria:

          -  Pregnant women and lactating mothers

          -  Ward of court or under guardianship

          -  Adult unable to express their consent

          -  Person deprived of freedom by judicial or administrative decision

          -  Person hospitalized without their consent

          -  Person under legal protection

          -  Precedent complete macroscopic tumor resective surgery

          -  No valid inclusion criteria

          -  Intratumoral hemorrhage MRI detected

          -  Treatment anticoagulant or antisludge treatments

          -  Active Infections and non controled or medical affection or psychiatric intercurrent
             non treated

          -  Evolutive cerebral oedema without corticoid response

          -  Non controled Epilepsy without antiepileptics response

          -  Karnofsky score &lt; 40%

          -  Weight &gt; 100 kg

          -  No possibility of resective surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François BERGER, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Grenoble Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
    <phone>+33 4 38 78 28 51</phone>
    <email>csandreballester@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CLINATEC</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <phone>+33 4 38 78 28 51</phone>
      <email>csandreballester@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>François BERGER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>November 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
